Home Alzheimer’s Disease Study Shows Increase in Lung Cancer Mortality, Decrease in Diagnosis During COVID-19...

Study Shows Increase in Lung Cancer Mortality, Decrease in Diagnosis During COVID-19 Pandemic

A retrospective study from Spain, presented in a press briefing during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC), found that the coronavirus disease 2019 (COVID-19) has had a significant impact on the diagnosis and prognosis of patients with lung cancer.

The study found that 38% fewer new lung cancer cases were diagnosed during COVID-19 compared with pre-COVID-19, with more symptomatic and severe cases of NSCLC being diagnosed during the pandemic period.

“Lung cancer diagnoses have been affected during COVID-19 with as little as 38% of new cases in non–small cell lung cancer, more symptomatic and severe cases were diagnosed, but not in small cell lung cancer,” said Roxana Reyes, MD.

In Spain, when a state of emergency was put into effect due to the pandemic, it forced the prioritization of healthcare services toward…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments